Evidence map›Paper›PMID 33924976›Full record

ArticleJournal of clinical medicine2021

Screening and Confirmatory Testing for SARS-CoV-2 Antibodies: Comparison of Health and Non-Health Workers in a Nationwide Healthcare Organization in Central Europe.

Johann Bartko, Sonja Zehetmayer, Lukas Weseslindtner, Karin Stiasny, Andrea Schloegl, Ernst Forjan, Elisabeth Zwettler, Andreas Krauter, Felix Keil, Nazanin Sédille-Mostafaie

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Johann BartkoInstitute for Laboratory Medicine, Hanusch Hospital, 1140 Vienna, Austria.ORCID 0000-0003-0487-7523
Sonja ZehetmayerCenter for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, 1140 Vienna, Austria.
Lukas WeseslindtnerCenter for Virology, Medical University of Vienna, 1090 Vienna, Austria.
Karin StiasnyCenter for Virology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-1902-8674
Andrea SchloeglInstitute for Laboratory Medicine, Hanusch Hospital, 1140 Vienna, Austria.
Ernst ForjanDepartment of Haemato-Oncology, Hanusch Hospital, 1090 Vienna, Austria.
Elisabeth ZwettlerMedical Directorate, Hanusch Hospital, 1140 Vienna, Austria.
Andreas KrauterMedical Services, Austrian Health Insurance Fund, 1030 Vienna, Austria.
Felix KeilDepartment of Haemato-Oncology, Hanusch Hospital, 1090 Vienna, Austria.
Nazanin Sédille-MostafaieInstitute for Laboratory Medicine, Hanusch Hospital, 1140 Vienna, Austria.
Hanusch Hospital · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite being located close to the European epicenter of the COVID-19 pandemic in Italy, Austria has managed to control the first wave. In Austria, the largest health insurance fund covers 7 million people and has 12,000 employees, including 3700 healthcare workers (HCW). For patient and staff safety, transmission control measures were implemented and mass testing of employees for SARS-CoV-2 antibodies was conducted. An IgG SARS-CoV-2 rapid test on fingerstick blood was used as a screening test (ST), followed by serologic studies with 3 different immunoassays and confirmatory testing by a neutralization test (NT). Among 7858 employees, 144 had a positive ST and 88 were confirmed by a NT (1.12%, CI: 0.9-1.38%). The positive predictive value (PPV) of the ST was 69.3% (CI: 60.5-77.2). Interestingly, 40% of the NT positive serum samples were tested negative in all 3 immunoassays. Of the total sample, 2242 HCW (28.5%) were identified. Unexpectedly, there was no difference in the prevalence of NT positives in HCW compared to non-HCW (23/2242 vs. 65/5301,

Indexed as

COVID-19health personnelSARS-CoV-2

Identifiers

PMID33924976
PMCPMC8124742
OpenAlexW3157878059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.